PL367959A1 - Inhibitory integryny do terapii chorób oczu - Google Patents

Inhibitory integryny do terapii chorób oczu

Info

Publication number
PL367959A1
PL367959A1 PL02367959A PL36795902A PL367959A1 PL 367959 A1 PL367959 A1 PL 367959A1 PL 02367959 A PL02367959 A PL 02367959A PL 36795902 A PL36795902 A PL 36795902A PL 367959 A1 PL367959 A1 PL 367959A1
Authority
PL
Poland
Prior art keywords
treatment
eye diseases
integrin inhibitors
integrin
inhibitors
Prior art date
Application number
PL02367959A
Other languages
English (en)
Other versions
PL207175B1 (pl
Inventor
Hans Markus Bender
Jutta Haunschild
Ulrich Lang
Matthias Wiesner
Martin Friedlander
Original Assignee
Merck Patent Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Patent Gmbh filed Critical Merck Patent Gmbh
Publication of PL367959A1 publication Critical patent/PL367959A1/pl
Publication of PL207175B1 publication Critical patent/PL207175B1/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/538—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with carbocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/351—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom not condensed with another ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/10—Ophthalmic agents for accommodation disorders, e.g. myopia

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
PL367959A 2001-08-01 2002-07-03 Zastosowanie inhibitorów integryny do wytwarzania kompozycji farmaceutycznych do zapobiegania i/lub terapii chorób oczu PL207175B1 (pl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US30885101P 2001-08-01 2001-08-01
PCT/EP2002/007377 WO2003013511A1 (en) 2001-08-01 2002-07-03 Integrin inhibitors for the treatment of eye diseases

Publications (2)

Publication Number Publication Date
PL367959A1 true PL367959A1 (pl) 2005-03-07
PL207175B1 PL207175B1 (pl) 2010-11-30

Family

ID=23195644

Family Applications (1)

Application Number Title Priority Date Filing Date
PL367959A PL207175B1 (pl) 2001-08-01 2002-07-03 Zastosowanie inhibitorów integryny do wytwarzania kompozycji farmaceutycznych do zapobiegania i/lub terapii chorób oczu

Country Status (20)

Country Link
US (2) US20040198644A1 (pl)
EP (1) EP1411926B1 (pl)
JP (1) JP2005504757A (pl)
KR (1) KR20040028966A (pl)
CN (1) CN1536998A (pl)
AR (1) AR036199A1 (pl)
AT (1) ATE296628T1 (pl)
AU (1) AU2002319282B2 (pl)
BR (1) BR0211604A (pl)
CA (1) CA2456076C (pl)
DE (1) DE60204466T2 (pl)
DK (1) DK1411926T3 (pl)
ES (1) ES2243744T3 (pl)
HU (1) HUP0401605A3 (pl)
MX (1) MXPA04000839A (pl)
PL (1) PL207175B1 (pl)
PT (1) PT1411926E (pl)
RU (1) RU2311177C2 (pl)
WO (1) WO2003013511A1 (pl)
ZA (1) ZA200401598B (pl)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8236352B2 (en) 1998-10-01 2012-08-07 Alkermes Pharma Ireland Limited Glipizide compositions
US8293277B2 (en) * 1998-10-01 2012-10-23 Alkermes Pharma Ireland Limited Controlled-release nanoparticulate compositions
US7198795B2 (en) * 2000-09-21 2007-04-03 Elan Pharma International Ltd. In vitro methods for evaluating the in vivo effectiveness of dosage forms of microparticulate of nanoparticulate active agent compositions
DK1471887T3 (da) 2002-02-04 2010-06-07 Elan Pharma Int Ltd Nanopartikelkompositioner der har lysozym som overfladestabiliseringsmiddel
JP4912881B2 (ja) * 2003-10-01 2012-04-11 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング 抗線維症薬としてのαｖβ３及びαｖβ６インテグリンアンタゴニスト
CN101120002A (zh) 2005-02-17 2008-02-06 惠氏公司 环烷基稠合的吲哚、苯并噻吩、苯并呋喃和茚衍生物
JP2008538576A (ja) * 2005-04-22 2008-10-30 ワイス クロマンおよびクロメン誘導体およびその使用
AU2008321770B2 (en) 2007-11-16 2012-09-06 Ube Industries, Ltd. Benzazepinone compound
WO2010113958A1 (ja) 2009-03-30 2010-10-07 宇部興産株式会社 眼の疾患の治療又は予防のための医薬組成物
CA2791278C (en) 2010-02-25 2015-11-24 The Johns Hopkins University Sustained delivery of therapeutic agents to an eye compartment
WO2012109363A2 (en) 2011-02-08 2012-08-16 The Johns Hopkins University Mucus penetrating gene carriers
EP2825207B1 (en) 2012-03-16 2020-08-19 The Johns Hopkins University Non-linear multiblock copolymer-drug conjugates for the delivery of active agents
AU2013232297B2 (en) 2012-03-16 2016-01-14 The Johns Hopkins University Controlled release formulations for the delivery of HIF-1 inhibitors
US8889730B2 (en) 2012-04-10 2014-11-18 Pfizer Inc. Indole and indazole compounds that activate AMPK
US9533068B2 (en) 2012-05-04 2017-01-03 The Johns Hopkins University Drug loaded microfiber sutures for ophthalmic application
US20150119792A1 (en) * 2012-05-08 2015-04-30 The Regents Of The University Of California Light degradable drug delivery system for ocular therapy
WO2014124006A1 (en) 2013-02-05 2014-08-14 The Johns Hopkins University Nanoparticles for magnetic resonance imaging tracking and methods of making and using thereof
EP2970177A1 (en) 2013-03-15 2016-01-20 Pfizer Inc. Indole compounds that activate ampk
CA2974715C (en) 2015-01-27 2020-05-05 The Johns Hopkins University Hypotonic hydrogel formulations for enhanced transport of active agents at mucosal surfaces
KR101748120B1 (ko) * 2015-07-13 2017-06-16 서울대학교산학협력단 나노입자-유리체 기반 단백질 복합체를 유효성분으로 포함하는 혈관신생억제용 조성물 및 이의 용도
JP2019501888A (ja) * 2015-12-04 2019-01-24 ヤンセン バイオテツク，インコーポレーテツド 前駆細胞を用いた網膜変性の治療
EA201991123A1 (ru) * 2016-11-08 2019-11-29 ИНДАЗОЛОВЫЕ ПРОИЗВОДНЫЕ В КАЧЕСТВЕ АНТАГОНИСТОВ ИНТЕГРИНА αV
KR102307767B1 (ko) * 2019-03-11 2021-10-01 서울대학교병원 망막맥락막 신생혈관성 질환을 진단하기 위한 인테그린 αvβ3 표적화 프로브 및 이의 제조 방법
US12496279B2 (en) 2019-04-11 2025-12-16 The Johns Hopkins University Nanoparticles for drug delivery to brain

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5753230A (en) * 1994-03-18 1998-05-19 The Scripps Research Institute Methods and compositions useful for inhibition of angiogenesis
MX9801228A (es) * 1995-08-14 1998-05-31 Scripps Research Inst METODOS Y COMPOSICIONES UTILES PARA LA INHIBICION DE ANGIOGENESIS MEDIADA POR ALFAV beta5.
DE19538741A1 (de) * 1995-10-18 1997-04-24 Merck Patent Gmbh Cyclopeptidderivate
US5904144A (en) * 1996-03-22 1999-05-18 Cytotherapeutics, Inc. Method for treating ophthalmic diseases
KR20000016301A (ko) * 1996-05-31 2000-03-25 빙검 더글라스 에이. 혈관 형성 억제에 유용한 방법 및 조성물
PT951295E (pt) * 1996-05-31 2010-07-29 Scripps Research Inst COMPOSIÎES PARA UTILIZAÆO NA INIBIÆO DE ANGIOGéNESE MEDIADA POR ALFA-V-BETA3
DE19705450A1 (de) * 1997-02-13 1998-08-20 Merck Patent Gmbh Bicyclische aromatische Aminosäuren
US6255353B1 (en) * 1998-03-13 2001-07-03 Centaur Pharmaceuticals, Inc. Inhibition of angiogenesis
US6489305B1 (en) * 1998-05-08 2002-12-03 Canji, Inc. Methods and compositions for the treatment of ocular diseases
US6378526B1 (en) * 1998-08-03 2002-04-30 Insite Vision, Incorporated Methods of ophthalmic administration
DE19850131A1 (de) * 1998-10-30 2000-05-04 Merck Patent Gmbh Chromenon- und Chromanonderivate
DE10006139A1 (de) * 2000-02-11 2001-08-16 Merck Patent Gmbh Indol-3-yl-Derivate

Also Published As

Publication number Publication date
KR20040028966A (ko) 2004-04-03
BR0211604A (pt) 2004-08-24
EP1411926B1 (en) 2005-06-01
AR036199A1 (es) 2004-08-18
US20060287225A1 (en) 2006-12-21
ES2243744T3 (es) 2005-12-01
PL207175B1 (pl) 2010-11-30
WO2003013511A1 (en) 2003-02-20
JP2005504757A (ja) 2005-02-17
RU2004106527A (ru) 2005-07-10
HUP0401605A3 (en) 2012-09-28
US7645736B2 (en) 2010-01-12
ATE296628T1 (de) 2005-06-15
PT1411926E (pt) 2005-10-31
CA2456076A1 (en) 2003-02-20
DK1411926T3 (da) 2005-08-29
CN1536998A (zh) 2004-10-13
DE60204466D1 (de) 2005-07-07
EP1411926A1 (en) 2004-04-28
AU2002319282B2 (en) 2007-06-28
US20040198644A1 (en) 2004-10-07
CA2456076C (en) 2011-08-23
RU2311177C2 (ru) 2007-11-27
MXPA04000839A (es) 2004-05-14
HUP0401605A2 (hu) 2004-11-29
ZA200401598B (en) 2004-11-17
DE60204466T2 (de) 2006-04-27

Similar Documents

Publication Publication Date Title
HUP0401605A3 (en) Integrin inhibitors for the treatment of eye diseases
IL159344A0 (en) Quinuclidines-substituted-multicyclic-heteroaryls for the treatment of disease
IL164784A0 (en) Diaryl urea derivatives useful for the treatment of protein kinase dependent diseases
AU2002310187A1 (en) Inhibitors of protein kinase for the treatment of disease
EG24420A (en) Treatment of ophthalmic conditions
IL196301A0 (en) Medicament for the treatment of hapatitis c
PL366636A1 (pl) Piranoindazole i ich zastosowanie w leczeniu jaskry
IL160884A0 (en) Azabicyclic-substituted fused-heteroaryl compounds for the treatment of disease
HUP0400024A3 (en) Combination for treatment of neoplastic diseases
PL371281A1 (pl) Sposoby i kompozycje do leczenia chorób oczu
AU3840802A (en) Methods and compositions for the treatment of diseases of the eye
EP1461030A4 (en) AMINOALKYL-BENZOFURAN-5-OL COMPOUNDS FOR THE TREATMENT OF GLAUCOMA
PL375564A1 (pl) Podstawione 5-chroman-5-ylo-etyloaminy i ich zastosowanie do leczenia jaskry
EP1455780A4 (en) NEW BENZODIFURANIMIDAZOLIN AND BENZOFURANIMIDAZOLIN DERIVATIVES AND THEIR USE FOR THE TREATMENT OF GLAUCOMA
GB0124124D0 (en) Methods of treatment
IL161748A0 (en) New use for the treatment of gastroesophageal reflux
HUP0402298A3 (en) Use of desoxypeganine for treating clinical depression
IL144949A0 (en) Treatment of prion diseases with dmso
GB0101146D0 (en) Treatment of skin conditions
GB2410744B (en) Kinase inhibitors for the treatment of disease
GB0100092D0 (en) Treatment of degenerative diseases
PT1706094T (pt) Tratamento de condições oftalmológicas
AU2002365654A8 (en) Treatment of diseases via the skin
SI1392292T1 (sl) Piranoindazoli in njihova uporaba pri zdravljenjuglavkoma
GB0312289D0 (en) Treatment of the eye

Legal Events

Date Code Title Description
LAPS Decisions on the lapse of the protection rights

Effective date: 20140703